Publication Details

The representatives of the pharmaceutical companies in Bangladesh, IP experts, professional, practitioners, and students from the Department of Law, University of Dhaka participated in this seminar. IP experts discussed the challenge, concerns and way forward for the pharmaceutical companies in Bangladesh after LDC graduation. Pharmaceutical companies in Bangladesh produce approximately 80% of generic medicines, and the remaining 20% are patented drugs. After LDC graduation, Pharmaceutical companies will not face any challenges for producing generic drugs, but they will face challenges for non-expiration of the term of the patented drugs applied before LDC graduation and new drug applications that will be filed after LDC graduation. To overcome these challenges, the Bangladesh Patent Act, 2022 was enacted and subsequently, repealed and new Bangladesh Patent Act, 2023 was enacted to mitigate the challenges for the pharmaceutical companies in Bangladesh. Thus, the Bangladesh Patent Act, 2023 provides the provisions for the Voluntary Licenses, Compulsory License, Parallel Importation, and Bolar exception, which will mitigate the challenges for the pharmaceutical companies in Bangladesh.